Recro Pharma Inc.'s (REPH) intravenous (IV) Meloxicam 30mg for the management of moderate to severe postoperative pain awaits the decision of FDA on March 24, 2019.The postoperative pain market, which is estimated to be about $5.9 billion, is dominated by opioids. Meloxicam IV belongs to the non-opioid class of drugs and is believed to overcome many of the issues associated with commonly prescribed opioid therapeutics, including respiratory depression, constipation, excessive nausea and vomiting, and devoid of addictive abuse potential while maintaining meaningful analgesic effects for pain relief.This is IV Meloxicam’s second go around with the FDA. Last May, the FDA declined to approve IV Meloxicam stating that the analgesic effects demonstrated in ad hoc analyses and selective secondary endpoints did not meet the agency's expectations. Will the second time be the charm for IV Meloxicam?REPH closed Tuesday’s trading at $8.37, down 0.83%.